OT Breast Cancer

Featured Content


New! Radiotherapy Cuts BRCA-Associated Contralateral Breast Cancer Risk

Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA mutation-associated breast cancers in a study from Israel reported in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.


Read More

New! Targeted Therapy in Breast Cancer Continues to Evolve

Most patients with ER-positive and HER2-positive breast cancer will do well on endocrine therapy for some time, but eventually almost all patients acquire resistance and require chemotherapy to maintain disease control.

Read More

New! PHEREXA Trial: Analyzing Overall Survival in HER2-Positive Metastatic Breast Cancer

This phase III, randomized, two-arm study (NCT01026142) evaluated the combination of trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer.


Read More

Article Library